Bluejay Diagnostics (BJDX) Competitors $1.71 -0.01 (-0.58%) Closing price 05/19/2026 04:00 PM EasternExtended Trading$1.69 -0.02 (-1.40%) As of 05/19/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock BJDX vs. NXL, BTCY, NVNO, PAVM, and LUCYShould you buy Bluejay Diagnostics stock or one of its competitors? MarketBeat compares Bluejay Diagnostics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bluejay Diagnostics include Nexalin Technology (NXL), Biotricity (BTCY), enVVeno Medical (NVNO), PAVmed (PAVM), and Innovative Eyewear (LUCY). These companies are all part of the "medical equipment" industry. BJDX vs. NXLBJDX vs. BTCYBJDX vs. NVNOBJDX vs. PAVMBJDX vs. LUCYHow does Bluejay Diagnostics compare to Nexalin Technology?Nexalin Technology (NASDAQ:NXL) and Bluejay Diagnostics (NASDAQ:BJDX) are both small-cap medical equipment companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership. Do insiders & institutionals have more ownership in NXL or BJDX? 0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 18.5% of Bluejay Diagnostics shares are held by institutional investors. 25.3% of Nexalin Technology shares are held by company insiders. Comparatively, 0.1% of Bluejay Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Is NXL or BJDX more profitable? Bluejay Diagnostics has a net margin of 0.00% compared to Nexalin Technology's net margin of -3,018.12%. Bluejay Diagnostics' return on equity of -144.27% beat Nexalin Technology's return on equity.Company Net Margins Return on Equity Return on Assets Nexalin Technology-3,018.12% -191.88% -166.43% Bluejay Diagnostics N/A -144.27%-115.00% Which has more volatility & risk, NXL or BJDX? Nexalin Technology has a beta of 3.56, meaning that its stock price is 256% more volatile than the broader market. Comparatively, Bluejay Diagnostics has a beta of 0.72, meaning that its stock price is 28% less volatile than the broader market. Does the media favor NXL or BJDX? In the previous week, Bluejay Diagnostics had 3 more articles in the media than Nexalin Technology. MarketBeat recorded 5 mentions for Bluejay Diagnostics and 2 mentions for Nexalin Technology. Bluejay Diagnostics' average media sentiment score of 1.18 beat Nexalin Technology's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nexalin Technology 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Bluejay Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable valuation & earnings, NXL or BJDX? Bluejay Diagnostics has lower revenue, but higher earnings than Nexalin Technology. Nexalin Technology is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNexalin Technology$300K22.02-$8.22M-$0.47N/ABluejay DiagnosticsN/AN/A-$6.85M-$11.63N/A Do analysts recommend NXL or BJDX? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nexalin Technology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 SummaryBluejay Diagnostics beats Nexalin Technology on 8 of the 12 factors compared between the two stocks.How does Bluejay Diagnostics compare to Biotricity?Bluejay Diagnostics (NASDAQ:BJDX) and Biotricity (NASDAQ:BTCY) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, media sentiment, valuation, profitability and analyst recommendations. Do analysts rate BJDX or BTCY? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Biotricity 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has preferable valuation and earnings, BJDX or BTCY? Bluejay Diagnostics has higher earnings, but lower revenue than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBluejay DiagnosticsN/AN/A-$6.85M-$11.63N/ABiotricity$12.06M0.38-$14.09M-$0.16N/A Is BJDX or BTCY more profitable? Bluejay Diagnostics has a net margin of 0.00% compared to Biotricity's net margin of -80.42%. Biotricity's return on equity of 0.00% beat Bluejay Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Bluejay DiagnosticsN/A -144.27% -115.00% Biotricity -80.42%N/A -188.47% Do insiders and institutionals hold more shares of BJDX or BTCY? 18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 3.9% of Biotricity shares are held by institutional investors. 0.1% of Bluejay Diagnostics shares are held by insiders. Comparatively, 10.1% of Biotricity shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, BJDX or BTCY? Bluejay Diagnostics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Biotricity has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market. Does the media favor BJDX or BTCY? In the previous week, Bluejay Diagnostics had 4 more articles in the media than Biotricity. MarketBeat recorded 5 mentions for Bluejay Diagnostics and 1 mentions for Biotricity. Bluejay Diagnostics' average media sentiment score of 1.18 beat Biotricity's score of 0.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bluejay Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biotricity 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryBluejay Diagnostics beats Biotricity on 7 of the 13 factors compared between the two stocks.How does Bluejay Diagnostics compare to enVVeno Medical?Bluejay Diagnostics (NASDAQ:BJDX) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation. Which has more volatility & risk, BJDX or NVNO? Bluejay Diagnostics has a beta of 0.72, suggesting that its share price is 28% less volatile than the broader market. Comparatively, enVVeno Medical has a beta of 1.08, suggesting that its share price is 8% more volatile than the broader market. Which has stronger earnings & valuation, BJDX or NVNO? enVVeno Medical is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBluejay DiagnosticsN/AN/A-$6.85M-$11.63N/AenVVeno MedicalN/AN/A-$19.47M-$25.54N/A Is BJDX or NVNO more profitable? enVVeno Medical's return on equity of -66.39% beat Bluejay Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Bluejay DiagnosticsN/A -144.27% -115.00% enVVeno Medical N/A -66.39%-60.42% Does the media prefer BJDX or NVNO? In the previous week, Bluejay Diagnostics had 5 more articles in the media than enVVeno Medical. MarketBeat recorded 5 mentions for Bluejay Diagnostics and 0 mentions for enVVeno Medical. Bluejay Diagnostics' average media sentiment score of 1.18 beat enVVeno Medical's score of 0.48 indicating that Bluejay Diagnostics is being referred to more favorably in the media. Company Overall Sentiment Bluejay Diagnostics Positive enVVeno Medical Neutral Do institutionals and insiders believe in BJDX or NVNO? 18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are owned by institutional investors. 0.1% of Bluejay Diagnostics shares are owned by company insiders. Comparatively, 15.0% of enVVeno Medical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer BJDX or NVNO? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00enVVeno Medical 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 SummaryenVVeno Medical beats Bluejay Diagnostics on 6 of the 11 factors compared between the two stocks.How does Bluejay Diagnostics compare to PAVmed?Bluejay Diagnostics (NASDAQ:BJDX) and PAVmed (NASDAQ:PAVM) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation. Do insiders and institutionals hold more shares of BJDX or PAVM? 18.5% of Bluejay Diagnostics shares are owned by institutional investors. Comparatively, 19.9% of PAVmed shares are owned by institutional investors. 0.1% of Bluejay Diagnostics shares are owned by insiders. Comparatively, 13.4% of PAVmed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate BJDX or PAVM? PAVmed has a consensus price target of $65.00, suggesting a potential upside of 915.63%. Given PAVmed's stronger consensus rating and higher possible upside, analysts plainly believe PAVmed is more favorable than Bluejay Diagnostics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00PAVmed 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Is BJDX or PAVM more profitable? Bluejay Diagnostics has a net margin of 0.00% compared to PAVmed's net margin of -21,914.12%. Bluejay Diagnostics' return on equity of -144.27% beat PAVmed's return on equity.Company Net Margins Return on Equity Return on Assets Bluejay DiagnosticsN/A -144.27% -115.00% PAVmed -21,914.12%-146.19%-18.39% Which has more volatility & risk, BJDX or PAVM? Bluejay Diagnostics has a beta of 0.72, meaning that its share price is 28% less volatile than the broader market. Comparatively, PAVmed has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Does the media refer more to BJDX or PAVM? In the previous week, PAVmed had 3 more articles in the media than Bluejay Diagnostics. MarketBeat recorded 8 mentions for PAVmed and 5 mentions for Bluejay Diagnostics. Bluejay Diagnostics' average media sentiment score of 1.18 beat PAVmed's score of -0.12 indicating that Bluejay Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bluejay Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PAVmed 0 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings & valuation, BJDX or PAVM? PAVmed has higher revenue and earnings than Bluejay Diagnostics. PAVmed is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBluejay DiagnosticsN/AN/A-$6.85M-$11.63N/APAVmed$70K91.43$400K-$37.40N/A SummaryPAVmed beats Bluejay Diagnostics on 9 of the 15 factors compared between the two stocks.How does Bluejay Diagnostics compare to Innovative Eyewear?Bluejay Diagnostics (NASDAQ:BJDX) and Innovative Eyewear (NASDAQ:LUCY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership. Is BJDX or LUCY more profitable? Bluejay Diagnostics has a net margin of 0.00% compared to Innovative Eyewear's net margin of -272.42%. Innovative Eyewear's return on equity of -83.37% beat Bluejay Diagnostics' return on equity.Company Net Margins Return on Equity Return on Assets Bluejay DiagnosticsN/A -144.27% -115.00% Innovative Eyewear -272.42%-83.37%-76.02% Do insiders and institutionals have more ownership in BJDX or LUCY? 18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 1.0% of Innovative Eyewear shares are held by institutional investors. 0.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 1.7% of Innovative Eyewear shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer BJDX or LUCY? In the previous week, Bluejay Diagnostics had 2 more articles in the media than Innovative Eyewear. MarketBeat recorded 5 mentions for Bluejay Diagnostics and 3 mentions for Innovative Eyewear. Bluejay Diagnostics' average media sentiment score of 1.18 beat Innovative Eyewear's score of 1.00 indicating that Bluejay Diagnostics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bluejay Diagnostics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Innovative Eyewear 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, BJDX or LUCY? Bluejay Diagnostics has a beta of 0.72, indicating that its share price is 28% less volatile than the broader market. Comparatively, Innovative Eyewear has a beta of 2.7, indicating that its share price is 170% more volatile than the broader market. Do analysts recommend BJDX or LUCY? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bluejay Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Innovative Eyewear 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Which has better valuation & earnings, BJDX or LUCY? Bluejay Diagnostics has higher earnings, but lower revenue than Innovative Eyewear. Innovative Eyewear is trading at a lower price-to-earnings ratio than Bluejay Diagnostics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBluejay DiagnosticsN/AN/A-$6.85M-$11.63N/AInnovative Eyewear$2.66M2.25-$7.59M-$1.69N/A SummaryBluejay Diagnostics and Innovative Eyewear tied by winning 6 of the 12 factors compared between the two stocks. Get Bluejay Diagnostics News Delivered to You Automatically Sign up to receive the latest news and ratings for BJDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BJDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BJDX vs. The Competition ExportMetricBluejay DiagnosticsMED INSTRUMENTS IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.78M$6.99B$6.24B$12.23BDividend YieldN/A1.69%2.80%5.32%P/E Ratio-0.1549.1920.7825.05Price / SalesN/A70.19531.2172.66Price / CashN/A24.4943.0954.25Price / Book0.426.249.816.83Net Income-$6.85M$158.81M$3.55B$335.69M7 Day Performance-3.93%-0.53%-2.11%-2.15%1 Month Performance-13.20%-5.74%-4.14%-2.47%1 Year Performance-77.62%-3.70%28.35%27.13% Bluejay Diagnostics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BJDXBluejay Diagnostics1.4879 of 5 stars$1.71-0.6%N/A-77.8%$1.78MN/AN/A9News CoveragePositive NewsNXLNexalin Technology0.2249 of 5 stars$0.34-0.4%N/A-74.7%$7.02M$275.58KN/A3News CoveragePositive NewsGap DownBTCYBiotricityN/A$0.24-0.2%N/A-65.6%$6.80M$12.06MN/A40Gap UpNVNOenVVeno Medical1.0057 of 5 stars$9.49+1.8%N/A-92.0%$6.36MN/AN/A30PAVMPAVmed2.2475 of 5 stars$6.35-2.3%$65.00+923.6%-66.1%$6.35M$70KN/A90Earnings Report Related Companies and Tools Related Companies Nexalin Technology Alternatives Biotricity Alternatives enVVeno Medical Alternatives PAVmed Alternatives Innovative Eyewear Alternatives Co-Diagnostics Alternatives HeartSciences Alternatives CollPlant Biotechnologies Alternatives Itonic Alternatives NexGel Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BJDX) was last updated on 5/20/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredI’m sounding the alarmMeta is cutting 10% of its workforce. Microsoft offered voluntary retirement to 7% of U.S. employees. Oracle, ...Porter & Company | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredThe one number Musk can't hide in the S-1When SpaceX files its S-1 in June, one number will stand out - power consumption. Running 1 million GPUs requi...Behind the Markets | SponsoredHe doesn't buy gold. He just profits from it.Former hedge fund manager Larry Benedict generated $274 million in profits - and Barron's ranked his fund in t...Brownstone Research | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bluejay Diagnostics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bluejay Diagnostics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
